BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Sold by Stephens Inc. AR

Stephens Inc. AR decreased its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 34.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,841 shares of the medical equipment provider’s stock after selling 18,963 shares during the period. Stephens Inc. AR’s holdings in BioLife Solutions were worth $922,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Raymond James & Associates boosted its position in shares of BioLife Solutions by 4.3% during the 3rd quarter. Raymond James & Associates now owns 139,997 shares of the medical equipment provider’s stock worth $3,506,000 after purchasing an additional 5,803 shares in the last quarter. GAMMA Investing LLC grew its position in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares during the period. SG Americas Securities LLC purchased a new position in BioLife Solutions in the third quarter valued at about $425,000. Meros Investment Management LP lifted its position in shares of BioLife Solutions by 1.7% during the 2nd quarter. Meros Investment Management LP now owns 399,803 shares of the medical equipment provider’s stock valued at $8,568,000 after acquiring an additional 6,586 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of BioLife Solutions by 5.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after acquiring an additional 753 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at BioLife Solutions

In other news, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the sale, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,593,412.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares of the company’s stock, valued at $2,883,097.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total value of $239,000.00. Following the sale, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,044 shares of company stock worth $645,105 over the last quarter. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Trading Up 1.4 %

Shares of BLFS stock opened at $25.92 on Wednesday. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -15.34 and a beta of 1.88. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $24.03 and a 200 day moving average price of $22.32. BioLife Solutions, Inc. has a twelve month low of $9.92 and a twelve month high of $26.73.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. The business had revenue of $28.33 million for the quarter, compared to the consensus estimate of $23.80 million. Research analysts forecast that BioLife Solutions, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BLFS has been the subject of several research reports. TD Cowen lifted their price objective on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. Craig Hallum lifted their price target on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. HC Wainwright initiated coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They issued a “buy” rating and a $29.00 price objective on the stock. Finally, Northland Securities lifted their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $26.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.